login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
SKYE BIOSCIENCE INC (SKYE) Stock News
USA
- NASDAQ:SKYE -
US83086J2006
-
Common Stock
1.45
USD
+0.12 (+9.02%)
Last: 10/21/2025, 8:00:02 PM
1.4697
USD
+0.02 (+1.36%)
After Hours:
10/21/2025, 8:00:02 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
SKYE Latest News, Press Relases and Analysis
All
Press Releases
16 days ago - By: Chartmill
- Mentions:
LXEH
FEMY
ARBK
SLDP
...
These stocks are moving in today's session
16 days ago - By: Chartmill
- Mentions:
XELB
LXEH
PALI
ARBK
...
Let's take a look at the stocks that are in motion in today's session.
4 days ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Skye Bioscience, Inc. - SKYE
9 days ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Skye Bioscience, Inc. - SKYE
13 days ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Skye Bioscience, Inc. - SKYE
16 days ago - By: Benzinga
- Mentions:
AMD
ONMD
QUBT
SPRB
...
Nasdaq Jumps Over 150 Points; Skye Bioscience Shares Plunge
16 days ago - By: Chartmill
- Mentions:
OMEX
AMD
LXEH
FEMY
...
Monday's session: gap up and gap down stocks
16 days ago - By: Chartmill
- Mentions:
SANM
AMD
XELB
ASNS
...
Wondering what's happening in today's pre-market session?
16 days ago - By: Skye Bioscience, Inc.
Skye Bioscience Reports Topline CBeyond™ Phase 2a Data from Nimacimab Monotherapy and Combination Clinical Trial
a month ago - By: Skye Bioscience, Inc.
Skye Presents Phase 1b Data for its Peripheral CB1-inhibiting Antibody, Nimacimab, at European Association for the Study of Diabetes (EASD) Annual Meeting
2 months ago - By: Skye Bioscience, Inc.
Skye’s CB1 Inhibitor, Nimacimab, Demonstrates Superior Weight Loss and Differentiated Mechanisms from Monlunabant, and Continues to Show Enhanced Combination with Tirzepatide with Durable Post-Treatment Weight Maintenance in DIO Model
2 months ago - By: Skye Bioscience, Inc.
Skye Completes 26-week Treatment Phase in Phase 2a CBeyond™ Study
2 months ago - By: Skye Bioscience, Inc.
Skye Bioscience to Host Virtual KOL Event and Provide Perspectives on Upcoming CBeyond™ Phase 2a Topline Clinical Data Readout
2 months ago - By: Skye Bioscience, Inc.
Skye Bioscience to Participate in Upcoming Investment and Medical Conferences
3 months ago - By: The Motley Fool
Skye (SKYE) Q2 R&D Soars 249% No Revenue
3 months ago - By: Skye Bioscience, Inc.
Skye Bioscience Reports Second Quarter 2025 Financial Results and Business Update
3 months ago - By: Benzinga
- Mentions:
GSAT
PGY
ADV
REAL
...
Earnings Scheduled For August 7, 2025
3 months ago - By: Skye Bioscience, Inc.
Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025
4 months ago - By: Yahoo Finance
- Mentions:
HROW
William Blair Initiates Coverage of Harrow (HROW) With an Outperform Rating
4 months ago - By: Skye Bioscience, Inc.
Skye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association’s 85th Scientific Sessions
4 months ago - By: Yahoo Finance
- Mentions:
PYPD
Analysts Predict Up to ~590% Spike for These 2 ‘Strong Buy’ Penny Stocks
4 months ago - By: Skye Bioscience, Inc.
Skye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association’s 85th Scientific Sessions
5 months ago - By: Zacks Investment Research
- Mentions:
NVO
LLY
CRBP
3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies
5 months ago - By: Skye Bioscience, Inc.
Skye Bioscience to Participate in Upcoming Investment Conferences
5 months ago - By: Skye Bioscience, Inc.
Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab
5 months ago - By: Skye Bioscience, Inc.
Skye Bioscience Clinical Model Demonstrating Necessity of Peripheral CB1 Inhibition for Weight Loss Presented at European Congress on Obesity
6 months ago - By: Skye Bioscience, Inc.
Skye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity
Please enable JavaScript to continue using this application.